To print: Select File and then Print from your browser's menu

Title: Modafinil Reduces Sleepiness In Parkinson's Disease

URL: http://www.journalsleep.org/citation/sleepdata.asp?citationid=2182

Sleep, 2002;25(8) 905-909. "Modafinil for the Treatment of Daytime Sleepiness in Parkinson´s Disease: A Double-blind, Randomized, Crossover, Placebo-controlled Polygraphic Trial"
01/16/2003 08:49:01 AM
By Robert Short

Modafinil reduces daytime sleepiness in patients with Parkinson's disease. Dr B Högl and colleagues of the Department of Neurology and Department of Biostatistics University of Innsbruck, Austria, conducted a double-blind, randomized, placebo-controlled crossover study with two 2-week treatment blocks, separated by a 2-week washout phase. The patients received placebo or modafinil (100 mg in the first week, 200 mg in the second week) as a single morning dose in a randomized cross-over order. Twelve patients completed the study out of the 15 patients with idiopathic Parkinson's disease and daytime sleepiness that were entered into the study. All patients had an Epworth sleepiness score of at least 10. Twelve patients completed the study (nine males, three females; mean age 65 years; mean disease duration 6.8 years). The Epworth scores were significantly improved with treatment with modafinil compared with placebo. However, latency to sleep in the test of "maintenance of wakefulness" was not significantly altered by modafinil treatment. The researchers concluded, "The results of this study suggest that modafinil improves daytime sleepiness in Parkinson's disease patients, at least on a subjective or behavioural level."

http://www.journalsleep.org/citation/sleepdata.asp?citationid=2182

Copyright © 2009 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content.